Optimizing Aspirin Use in Obese Type 2 Diabetes Patients with Atherogenic Dyslipidemia: How to Identify Ideal Candidates

India’s Growing Triple Syndemic: Obesity, Type 2 Diabetes, and Atherogenic Dyslipidemia

Overview of the Syndemic

India is currently confronting a rapidly escalating triple syndemic comprising obesity, type 2 diabetes (T2D), and atherogenic dyslipidemia. These conditions frequently overlap and exacerbate each other’s cardiovascular risks. It is estimated that over 90% of individuals with diabetes exhibit an atherogenic lipid profile. Additionally, even those Indians classified as “lean” with non-alcoholic fatty liver disease (NAFLD) often display visceral fat accumulation, insulin resistance, and inflammation risks akin to those seen in obesity. Approximately 41.9% of Indians with T2D and dyslipidemia already show signs of atherogenic dyslipidemia.

Cardiovascular Risks Associated with the Syndemic

Patients suffering from the combination of obesity, T2D, and dyslipidemia face about a 1.4-fold increased risk of major cardiovascular events, such as myocardial infarction and stroke, compared to individuals with normal lipid profiles, even when their blood pressure is adequately controlled. Moreover, elevated lipoprotein(a) [Lp(a)] poses an independent, genetically determined atherogenic risk. Over 25% of Indian T2D patients have high Lp(a) levels, which tend to increase with the duration of diabetes. This article discusses the implications of this high-risk phenotype in India and the potential for earlier aspirin intervention.

Pathophysiological Interactions: The Impact of Obesity and Platelet Hyperreactivity

Mechanisms of Interaction

The interplay of insulin resistance, visceral adiposity, and chronic low-grade inflammation results in the production of reactive oxygen species (ROS) and cytokines, such as TNF-α, IL-6, and C-reactive protein (CRP). These factors contribute to endothelial dysfunction and increased platelet reactivity. Atherogenic dyslipidemia further accelerates plaque instability mediated by small dense LDL, even before overt atherosclerotic cardiovascular disease (ASCVD) manifests. In this context, the antiplatelet properties of low-dose aspirin become crucial for mitigating platelet activation prior to the occurrence of primary cardiovascular events.

Identifying Candidates for Aspirin Therapy

Ideal Profile for Aspirin Use

Aspirin appears particularly beneficial for obese, insulin-resistant T2D patients with high triglycerides, low HDL cholesterol, elevated non-HDL cholesterol, or increased Lp(a) levels. This subgroup exhibits heightened thromboxane-mediated platelet activation and inflammation, suggesting that precise risk stratification is essential rather than a blanket recommendation for aspirin use. Aspirin is most relevant when the risk of ASCVD-related macrovascular events substantially outweighs concerns about bleeding, particularly for individuals with early vascular stiffness or a significant family history of ASCVD. In such lipid-inflamed states, early platelet activation makes aspirin a viable consideration for selected high-risk profiles.

Current Guidelines on Aspirin Use

Guideline Recommendations

Current recommendations from the United States Preventive Services Task Force (USPSTF), the European Society of Cardiology (ESC), the American Heart Association/American College of Cardiology (AHA/ACC), and the Diabetes Cardiometabolic Risk Management (DCRM) 2024 guidelines endorse the individualized use of low-dose aspirin. The DCRM 2.0 guidelines suggest considering aspirin when two or more difficult-to-modify cardiovascular risk enhancers are present, including elevated non-HDL cholesterol, elevated LDL cholesterol, high Lp(a), low HDL cholesterol, diabetes, hypertension, chronic kidney disease, smoking, family history of ASCVD, and a coronary artery calcium (CAC) score over 100, provided there is a low risk of bleeding. The forthcoming ESC 2025 update reinforces this stance by formally recognizing elevated Lp(a) as a causal risk factor where aspirin has demonstrated meaningful ASCVD risk reduction.

Evidence Supporting Aspirin’s Role

A meta-analysis involving 49,871 participants presented at the ESC Congress 2025 indicated that aspirin significantly lowered the incidence of major adverse cardiovascular events in individuals with elevated Lp(a) levels of 50 mg/dL or higher, as well as in carriers of the rs-3798220-C/LPA variant, without increasing bleeding risk. This further substantiates aspirin’s potential for primary prevention in populations with genetically or biochemically high Lp(a) levels.

Conclusion: Key Takeaways

India’s metabolic phenotype poses an exceptionally high risk, characterized by obesity, type 2 diabetes, and atherogenic dyslipidemia; these conditions may also manifest in lean individuals with NAFLD. Early platelet hyperreactivity is prevalent among those with high triglycerides, low HDL cholesterol, or elevated Lp(a). In such high-risk profiles, the use of aspirin should be considered when macrovascular ASCVD risk predominates over bleeding concerns, utilizing a systematic and individualized approach.

Abbreviations

AD – Atherogenic Dyslipidemia, ACS – Acute Coronary Syndrome, AHA – American Heart Association, ASCVD – Atherosclerotic Cardiovascular Disease, CAC – Coronary Artery Calcium, CKD – Chronic Kidney Disease, CRP – C-Reactive Protein, CV – Cardiovascular, DCRM – Diabetes Cardiometabolic Risk Management, ESC – European Society of Cardiology, HDL-C – High-Density Lipoprotein Cholesterol, IL-6 – Interleukin-6, LDL-C – Low-Density Lipoprotein Cholesterol, Lp(a) – Lipoprotein(a), MI – Myocardial Infarction, NAFLD – Non-Alcoholic Fatty Liver Disease, PCOS – Polycystic Ovary Syndrome, ROS – Reactive Oxygen Species, T2D – Type 2 Diabetes, TG – Triglycerides, TNF-α – Tumor Necrosis Factor-alpha, USPSTF – United States Preventive Services Task Force.